Watch CTKB. Know when insiders buy.
One email the day a filing lands. Free.
CTKB
Cytek Biosciences, Inc.
4.53
−0.20 −4.23%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
45
WATCH · shorts 45
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $588.8MP/E —DIV YIELD —FCF YIELD -2.05%REV TTM $206.7M +5.4%NET INCOME −$80.6MNET CASH —52W 3.36 – 5.88SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $48.1M | +5.6% | 58.9% | −$11.4M | −$12.2M | — | — | $1.4M | $2.2M | −$849K | Aug 5 |
| Q1 2026 · Mar 31 | $44.1M | +6.5% | 48.2% | −$18.5M | −$18.9M | — | — | −$2.7M | $2.2M | −$4.9M | Aug 5 |
| Q4 2025 · Dec 31derived | $62.1M | +8.1% | 52.9% | −$5.6M | −$44.1M | −557.1% | — | −$771K | $1M | −$1.8M | Feb 26 |
| Q3 2025 · Sep 30 | $52.3M | +1.5% | 52.7% | −$9.2M | −$5.5M | −682.1% | — | −$3.9M | $657K | −$4.6M | Nov 5 |
| Q2 2025 · Jun 30 | $45.6M | −2.2% | 52.3% | −$10.6M | −$5.6M | — | — | $108K | $1.6M | −$1.5M | Aug 5 |
| Q1 2025 · Mar 31 | $41.5M | −7.6% | 48.6% | −$15M | −$11.4M | — | — | −$125K | $849K | −$974K | Aug 5 |
| Q4 2024 · Dec 31 | $57.5M | −1.3% | 58.5% | $3M | $9.6M | +75.2% | — | $2M | $894K | $1.1M | Feb 26 |
| Q3 2024 · Sep 30 | $51.5M | +7.3% | 56.3% | −$4.2M | $941K | — | — | $13.2M | $1M | $12.2M | Nov 5 |
| Q2 2024 · Jun 30 | $46.6M | — | 54.6% | −$8.5M | −$10.4M | — | — | $6.2M | $1.1M | $5.2M | Nov 5 |
| Q1 2024 · Mar 31 | $44.9M | — | 51.3% | −$10.7M | −$6.2M | — | — | $4M | $567K | $3.4M | May 8 |
| Q4 2023 · Dec 31 | $58.2M | — | 56.8% | −$137K | $5.5M | — | — | $9.5M | $1.5M | $8M | Feb 26 |
| Q3 2023 · Sep 30 | $48M | — | 56.6% | −$6.4M | −$6.5M | — | — | −$4.2M | $1.3M | −$5.6M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $201.5M | 51.8% | −$40.4M | −$66.5M | -33.0% | — | −$4.7M | $4.1M | −$8.8M | $15.1M | — |
| FY2024 · to Dec 31 | $200.5M | 55.4% | −$20.5M | −$6M | -3.0% | — | $25.4M | $3.5M | $21.9M | $21.6M | — |
| FY2023 · to Dec 31 | $193M | 56.7% | −$27.8M | −$12.1M | -6.3% | -0.09 | $5.3M | $4.6M | $633K | $44.2M | — |
| FY2022 · to Dec 31 | $3M | 3407.8% | −$1.8M | $2.5M | 83.8% | 0.02 | −$12.2M | $9.7M | −$22M | $0 | — |
| FY2021 · to Dec 31 | $2.2M | 3628.8% | $9.2M | $3M | 138.8% | 0.00 | $4.6M | $4.4M | $266K | $0 | — |
| FY2020 · to Dec 31 | $710K | 7283.1% | $13.7M | $19.4M | 2733.9% | 0.10 | $15.2M | $1.5M | $13.6M | — | — |
Every number comes from Cytek Biosciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.